Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

NCT03629756 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT03629756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03629756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 24, 2018
Completion date
September 3, 2021
Enrollment
48 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, castration-resistant prostate cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, melanoma, merkel cell carcinoma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck